The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A N-sulfonylcarboxamide resulting from the formal condensation of the carboxy group of 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}benzoic acid with the amino group of 4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide. It is a BH3-mimetic drug which targets the anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, and induces apoptosis in cancer cells. Currently under clinical investigation as treatment for solid tumors and hematologic malignancies.
navitoclax results in decreased expression of BIRC5 protein [MTOR protein affects the susceptibility to navitoclax] which affects the expression of BIRC5 protein; navitoclax promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]
navitoclax results in increased cleavage of CASP3 protein [navitoclax co-treated with GSK923295] results in increased activity of CASP3 protein; [navitoclax co-treated with Vorinostat] results in increased activity of CASP3 protein
MTOR protein affects the susceptibility to navitoclax [MTOR protein affects the susceptibility to navitoclax] which affects the cleavage of PARP1 protein; [MTOR protein affects the susceptibility to navitoclax] which affects the expression of BIRC5 protein
[MTOR protein affects the susceptibility to navitoclax] which affects the cleavage of PARP1 protein; [navitoclax co-treated with Everolimus] results in increased cleavage of PARP1 protein; rucaparib promotes the reaction [navitoclax results in increased cleavage of PARP1 protein]
browse the term
